Plasma amyloid-beta oligomer and phosphorylated tau:diagnostic tools for progressive Alzheimer's disease  

作　　者：Seong Soo A.An John P.Hulme 

机构地区：[1]Department of Bionano Technology,Gachon Bionano Research Institute,Gachon University,Seongnam-si,Gyeonggi-do,South Korea

出　　处：《Neural Regeneration Research》2023年第11期2391-2392,共2页中国神经再生研究（英文版）

基　　金：National Research Foundation of Korea (NRF) by the Korean Government (2020R1A2B5B01002463&2021R1A6A1A03038996)(to JPH)。

摘　　要：Introduction:Spanning the three stages of the Alzheimer’s disease (AD) continuum,amyloid-beta(Aβ40and Aβ42) oligomers (AβO’s) and tau protein constitute a set of biomarkers ideally suited for the non-invasive monitoring of AD (Wolgin et al.,2022).AD progression is correlated with the presence of low molecular weight oligomers and not amyloid plaques.Moreover,low molecular weight AβO is present in the beginning and later stages of disease even when the plaque burden becomes prevalent.Furthermore.

关 键 词：AMYLOID TAU ALZHEIMER 

分 类 号：R749.16[医药卫生—神经病学与精神病学]